LOS ANGELES — DeciBio Consulting, a strategic advisory firm specializing in precision medicine, has promoted Carl Schoellhammer, Ph.D., to Partner. Schoellhammer leads the firm’s advanced therapies practice and serves as Managing Director of the DeciBio BroadOak BioTools Venture Fund, a collaborative initiative between DeciBio Ventures and BroadOak Capital Partners.
Schoellhammer brings a distinctive combination of scientific, entrepreneurial, and strategic insight to his role. Since joining DeciBio, he has advised leading biopharma and biotech companies on areas including therapeutic prioritization, pipeline strategy, and bioprocess optimization, with a strong emphasis on cell and gene therapies. He has also played a key role in shaping the firm’s early-stage investment portfolio through DeciBio Ventures, which he has helped lead since its inception in 2021.
“We’re thrilled to welcome Carl Schoellhammer to the DeciBio partnership,” said Stephane Budel, co-founding partner at DeciBio. “Carl has been instrumental in building and scaling our cell and gene therapy practice, bringing deep domain expertise, strategic vision, and a collaborative spirit that embodies the values of our firm. His leadership will be key as we continue to expand our impact in precision medicine and support our clients at the forefront of therapeutic innovation.”
Prior to joining DeciBio, Schoellhammer co-founded Suono Bio, a Massachusetts Institute of Technology (MIT) spinout with Professor Robert Langer, where he served as founding CEO. The company developed novel ultra-rapid drug delivery platforms targeting inflammatory diseases. Schoellhammer holds a Ph.D. in chemical engineering from MIT and a B.S. from the University of California, Berkeley.
Explaining his decision to join the partnership, Schoellhammer said, “The thought leadership. We are a nimble, boutique consultancy that really prides itself on our entrepreneurship and the number of initiatives we can do. Joining the partnership now will allow me to have more of a say in some of the firm’s direction, and I think we are poised for exciting growth.”
His promotion highlights DeciBio’s ongoing commitment to developing visionary leaders and advancing its mission to support innovation across the precision medicine landscape.
